var data={"title":"Dinoprostone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Dinoprostone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6043?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=dinoprostone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Dinoprostone: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708703\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use dinoprostone, as with other potent oxytocic agents, only with strict adherence to recommended dosages. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Dinoprostone should be used by medically trained personnel in a hospital that can provide immediate intensive care and acute surgical facilities.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160960\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cervidil;</li>\n      <li>Prepidil;</li>\n      <li>Prostin E2</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160961\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Cervidil;</li>\n      <li>Prepidil;</li>\n      <li>Prostin E<sub>2</sub></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161000\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Abortifacient;</li>\n      <li>\n        Prostaglandin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160964\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Termination of intrauterine pregnancy:</b> <i>Vaginal suppository:</i> Insert 20 mg (1 suppository) high in vagina, repeat at 3- to 5-hour intervals until abortion occurs; continued administration for longer than 2 days is not advisable</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cervical ripening:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Endocervical gel:</i> Using catheter supplied with gel, insert 0.5 mg into the cervical canal. May repeat every 6 hours if needed. Maximum cumulative dose: 1.5 mg/24 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Tablet (oral) [Canadian product]:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Induction: Initial: 0.5 mg and then repeat 0.5 mg dose 1 hour later; may give additional 0.5 mg dose on an hourly basis as needed for satisfactory uterine response. Maintain patient at the lowest effective dose. <b>Note:</b> Failure to induce regular contractions after 8 hours indicates failed induction and alternative management of patient should be considered. If patient vomits an intact tablet during therapy repeat dose. If patient vomits intact tablets following 2 successive doses, withhold therapy until next scheduled dose. If patient vomits a partial tablet or if no tablet is visible, continue at next regularly scheduled dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Parity &ge;2 times or Bishop Score of &ge;6: Administer 0.5 mg hourly throughout induction (discontinue hourly dose for excessive uterine activity)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Nulliparous or multiparous and resistant to induction (Bishop Score &lt;6): If inadequate response after 2 hours of therapy may increase dose in 0.5 mg increments at hourly intervals up to a maximum single dose of 1.5 mg.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance of labor: 0.5 mg dose; may occasionally withhold hourly dose to assess need for further dosing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Vaginal gel [Canadian product]:</i> Initial: Using prefilled syringe, insert 1 mg into the posterior fornix of the vaginal canal; may give 1 additional dose of 1-2 mg 6 hours later if needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Vaginal insert:</i> Insert 10 mg transversely into the posterior fornix of the vagina (to be removed at the onset of active labor or after 12 hours).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3946482\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">Females of reproductive age: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160943\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, Vaginal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prepidil: 0.5 mg/3 g (3 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Insert, Vaginal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cervidil: 10 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suppository, Vaginal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Prostin E2: 20 mg (5 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160929\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15671160\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, vaginal:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prostin E<sub>2</sub>: 1 mg/3 g (3 g), 2 mg/3 g (3 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Prostin E<sub>2</sub>: 0.5 mg [contains lactose]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160945\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocervical gel: Bring to room temperature just prior to use. Do not force the warming process (eg, water bath, microwave). Avoid contact with skin while handling; wash hands thoroughly with soap and water after administration. For cervical ripening, patient should be supine in the dorsal position. The appropriate catheter length should be based on degree of effacement; 20 mm for no effacement; 10 mm if 50% effaced. Patient should remain supine for 15-30 minutes following administration. The manufacturer recommends waiting 6-12 hours after dinoprostone gel administration before initiating oxytocin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet (oral) [Canadian product]: Administer with small amount of water. Use of oxytocin should be avoided until &ge;1 hour after administration of the last oral tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaginal gel: [Canadian product]: For intravaginal use only (not for intracervical use). Using prefilled syringe, dose is placed in the posterior fornix of the vagina. Patient should remain in lateral or supine position for 30 minutes to prevent leakage. Syringe contains overfill and is designed to deliver a dose of 1 mg or 2 mg dinoprostone. Syringe is for single use only. Use of oxytocin should be avoided for 12-24 hours after administration of vaginal gel.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaginal insert: Keep frozen until use; product does not need warmed prior to use. Only open package along the tear mark; do not open with sharp objects which may compromise or cut the knitted polyester pouch which is the retrieval system for the polymeric slab. To use, remove from the foil package and immediately place one vaginal insert transversely in the posterior fornix of the vagina. A water miscible lubricant may be used to facilitate insertion (avoid excessive use of lubricant which could prevent optimal swelling and release of dinoprostone from the vaginal insert). Patients should remain in the recumbent position for 2 hours after insertion, but thereafter may be ambulatory (ensure the vaginal insert remains in place). Do not use without retrieval system. Ensure complete removal of system at completion of therapy. The manufacturer recommends waiting &ge;30 minutes after removing the dinoprostone vaginal insert before initiating oxytocin.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaginal suppository: Insert high into vagina after removal from its foil package. Bring to room temperature just prior to use. Patient should remain supine for 10 minutes following insertion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132414\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 3]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage. NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160944\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;\">\n      <b>Cervical ripening</b> <b>and labor induction:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocervical gel (Prepidil): Promote cervical ripening in patients at or near term in whom there is a medical or obstetrical indication for the induction of labor</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablet (oral) (Prostin E<sub>2</sub>; [Canadian product]): Elective induction of labor; when indications for induction of labor exist (eg, premature rupture of amniotic membranes, toxemia of pregnancy, Rh incompatibility, diabetes mellitus, hypertension, postmaturity, intrauterine death or fetal growth retardation)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vaginal gel (Prostin E<sub>2</sub>; [Canadian product]): Induction of labor in patients at or near term with singleton pregnancy, vertex presentation, and favorable induction features</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Vaginal insert (Cervidil): Initiation and/or continuation of cervical ripening in patients at or near term in whom there is a medical or obstetrical indication for the induction of labor</p>\n    <p style=\"text-indent:0em;\">\n      <b>Termination of intrauterine pregnancy: </b>Suppositories (Prostin E<sub>2</sub>): Terminate pregnancy from 12th through 20th week of gestation; evacuate uterus in cases of missed abortion or intrauterine fetal death up to 28 weeks of gestation; manage benign hydatidiform mole (nonmetastatic gestational trophoblastic disease)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F161006\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Prostin E2 may be confused with Prostin VR (alprostadil)</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Cervidil brand name for dinoprostone [U.S., Canada, Australia, New Zealand], but also the brand name for gemeprost [Italy]</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Different formulations: Dinoprostone is available as a vaginal gel (Prepidil), insert (Cervidil), and suppository (Prostin E<sub>2</sub>).  Prepidil and Cervidil are used to promote cervical ripening while Prostin E<sub>2</sub> is used to evacuate the uterine contents in cases of missed abortion or intrauterine fetal death. Medication errors have occurred when Prostin E<sub>2</sub> suppository was cut in half and administered to induce labor (Institute for Safe Medication Practices [ISMP] 2013).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160936\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Endocervical gel: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Localized warm feeling (vagina; 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Gastrointestinal distress (6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Uterine contractions (abnormal 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain (3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Amnionitis, amniotic fluid embolism (anaphylactoid syndrome of pregnancy), disseminated intravascular coagulation (postpartum), hypersensitivity reaction (including anaphylaxis, anaphylactic shock, and anaphylactoid reaction), premature rupture of membranes, uterine rupture (with intracervical administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Suppository: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Cardiac arrhythmia, chest pain, chest tightness, hypotension, syncope</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Chills, dizziness, headache, paresthesia, shivering, tension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis, skin discoloration, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Dehydration, hot flash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea, endometritis, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Breast tenderness, urinary retention, uterine rupture, vaginal pain, vaginismus, vaginitis, vulvitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis (new or exacerbated), back pain, leg cramps (nocturnal), muscle cramps, myalgia, neck stiffness, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Blurred vision, eye pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Otic: Auditory impairment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Cough, dyspnea, laryngitis, pharyngitis, wheezing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Myocardial infarction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Tablets (oral) [Canadian product]: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Frequency not always defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Cardiovascular: Amniotic fluid embolism (pulmonary), cardiac arrest</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Central nervous system: Malaise (transient vasovagal symptoms)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Gastrointestinal: Vomiting (with or without nausea/diarrhea: 21% to 50%; dose dependent)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Genitourinary: Hypertonic uterine contractions (3%), cervical dilation (rapid), placental abruption, uterine contractions (abnormal), uterine rupture</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, anaphylactic shock, and nonimmunologic anaphylaxis [formerly known as anaphylactoid reaction])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Respiratory: Asthma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Bronchospasm, chills, disseminated intravascular coagulation, dizziness, dyspnea, fever, flushing, headache, hiccups, hypertension, hypotension, postpartum hemorrhage, skin rash, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Vaginal gel [Canadian product]: </b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Frequency not always defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Cardiovascular: Cardiac arrest</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Central nervous system: Localized warm feeling (vagina)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Gastrointestinal: Diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Genitourinary: Hypertonic uterine contractions (3%), uterine contractions (abnormal), uterine rupture</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis, anaphylactic shock, and nonimmunologic anaphylaxis [formerly known as anaphylactoid reaction])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&lt;1%, postmarketing and/or case reports: Disseminated intravascular coagulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">\n      <b>Vaginal insert:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\"> Genitourinary: Hypertonic uterine contractions (<i>without</i> fetal distress 2% to 5%, <i>with</i> fetal distress 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&lt;1% postmarketing and/or case reports: Abdominal pain, amniotic fluid embolism (anaphylactoid syndrome of pregnancy), diarrhea, disseminated intravascular coagulation (postpartum), fever, hypersensitivity reaction, hypotension, nausea, uterine rupture, vomiting</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160948\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Generally, labor induction is contraindicated whenever spontaneous labor or vaginal delivery is contraindicated (ACOG 2009); manufacturer specific contraindications are listed by dosage form.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">All dosage forms: Hypersensitivity to prostaglandins or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocervical gel: Patients in whom oxytocic drugs are contraindicated including: History of cesarean section or major uterine surgery; presence of cephalopelvic disproportion; fetal distress when delivery is not imminent; unexplained vaginal bleeding during this pregnancy; history of difficult labor and/or traumatic delivery; &ge;6 previous term pregnancies with nonvertex presentation; hyperactive or hypertonic uterine patterns; obstetric emergencies when surgical intervention would be favorable. Use is also contraindicated with placenta previa or when vaginal delivery is not indicated (eg, vasa previa, active herpes genitalia)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): History of epilepsy; fetal malpresentation; overdistention of the uterus (multiple pregnancies, polyhydramnios); ruptured amniotic membranes or suspected chorioamnionitis; concurrent use with other oxytocics</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suppository: Acute pelvic inflammatory disease; active cardiac, pulmonary, renal, or hepatic disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet (oral) [Canadian product]: Patients in whom oxytocic drugs are generally contraindicated or where prolonged contractions of the uterus are considered inappropriate. Active cardiac, pulmonary, renal or hepatic disease; simultaneous use with other oxytocics; history of cesarean section or major uterine surgery; presence of cephalopelvic disproportion; history of difficult labor and/or traumatic delivery; &ge;6 pregnancies; suspected or clinically evident preexisting fetal distress; overdistention of the uterus (multiple pregnancy, polyhydramnios); preexisting uterine hypertonus; situations where a responsible physician is unavailable; engagement of head not taken place; unexplained vaginal bleeding during this pregnancy; fetal malpresentation; gynecological, obstetrical or medical conditions that preclude vaginal delivery; pregnancy complicated by abnormal position of the placenta or umbilical cord; history of or existing pelvic inflammatory disease unless adequately treated</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaginal gel [Canadian product]: Simultaneous use with other oxytocics; history of cesarean section or major uterine surgery; presence of cephalopelvic disproportion; history of difficult labor and/or traumatic delivery; &ge;6 term pregnancies; suspected or clinically evident preexisting fetal distress; overdistention of the uterus (multiple pregnancy, polyhydramnios); preexisting uterine hypertonus; situations where a responsible physician is unavailable; engagement of head not taken place; unexplained vaginal bleeding during this pregnancy; fetal malpresentation; gynecological, obstetrical or medical conditions that preclude vaginal delivery; pregnancy complicated by abnormal position of the placenta or umbilical cord; ruptured amniotic membranes or suspected chorioamnionitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaginal insert: Patients in whom oxytocic drugs are contraindicated; history of cesarean section or major uterine surgery; presence of cephalopelvic disproportion; fetal distress when delivery is not imminent; unexplained vaginal bleeding during this pregnancy; patients already receiving IV oxytocic drugs; &ge;6 previous term pregnancies</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in US labeling): Placenta previa; history of difficult labor and/or traumatic delivery; overdistention of the uterus (multiple pregnancies, polyhydramnios); fetal malpresentation; history of uncontrolled epilepsy; history of or existing pelvic inflammatory disease unless adequately treated</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160933\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid syndrome of pregnancy: Intracervical placement of endocervical gel, vaginal gel or vaginal insert may lead to anaphylactoid syndrome of pregnancy (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Disseminated intravascular coagulation (DIC): Postpartum DIC has been reported following dinoprostone for labor induction. Risk may be increased in women &ge;30 years of age, gestation age &gt;40 weeks, or women with pregnancy complications.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Serious life-threatening hypersensitivity reactions, including anaphylaxis and angioedema, have been noted. Onset of reactions may occur within minutes to hours following initiation of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use caution in patients with cardiovascular disease; manufacturer labeling for some dosage forms contraindicate use in active cardiovascular disease (refer to contraindications field).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Epilepsy: Use with caution in patients with epilepsy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glaucoma: Use caution in patients with glaucoma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use caution in patients with hepatic impairment; manufacturer labeling for some dosage forms (eg, suppository, tablet, vaginal gel) contraindicate use in active hepatic disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pulmonary disease: Use caution in patients with a history of asthma; manufacturer labeling for some dosage forms (eg, suppository, tablet, vaginal gel) contraindicate use with active pulmonary disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use caution in patients with renal impairment; manufacturer labeling for some dosage forms (eg, suppository, tablet, vaginal gel) contraindicate use in active renal disease.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Endocervical gel: Use caution with ruptured membranes.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Suppository: When used for termination of pregnancy, dinoprostone is not considered feticidal, but is used to terminate pregnancy due to its ability to stimulate uterine contractions; do not use if fetus has reached the stage of viability. Transient pyrexia and decreased blood pressure may be observed with treatment. Use caution with history of hypotension or hypertension; cardiovascular disease; anemia; jaundice; diabetes; compromised uteri; cervicitis, endocervical infections or acute vaginitis. Measures should be taken to ensure complete abortion. Commercially available suppositories should not be used for extemporaneous preparation of any other dosage form of drug. Do not use for cervical ripening or other indications in patients with term pregnancy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaginal gel [Canadian product]: For intravaginal use only; not for intracervical use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaginal insert: Use caution with ruptured membranes; nonvertex or nonsingleton pregnancy or previous uterine hypertony. Must be removed prior to administration of oxytocin, in case of hyperstimulation or if labor begins, fetal distress, maternal distress (eg, hypotension, nausea, tachycardia, vomiting), and prior to amniotomy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced personnel: <b>[US Boxed Warning]: Dinoprostone should be used only by medically-trained personnel in a hospital with strict adherence to recommended doses.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299208\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160938\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9368&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Carbetocin: Dinoprostone may enhance the adverse/toxic effect of Carbetocin. Specifically, Carbetocin oxytocic effects may be enhanced. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carboprost Tromethamine: May enhance the adverse/toxic effect of Oxytocic Agents. Specifically, oxytocic effects may be enhanced.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxytocin: Dinoprostone may enhance the adverse/toxic effect of Oxytocin. Specifically, oxytocic effects may be enhanced.  Management: Concomitant use of dinoprostone and oxytocin is not recommended. If used sequentially, monitor uterine activity closely. Administer oxytocin 30 minutes after removing dinoprostone vaginal insert and 6 to 12 hours after the application of dinoprostone gel.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3946439\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events have been observed in animal reproduction studies. Although these effects would not be expected in humans when administered after the period of organogenesis, a sustained increase in uterine tone may have increased risks of adverse events to the fetus.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Fetal distress without corresponding maternal uterine hyperstimulation was observed in 3% to 4% of infants exposed to Cervidil in utero<i>.</i> No adverse effects on physical or psychomotor function were observed in a 3 year follow-up study of exposed infants. Abnormal fetal heart rates were observed in 17% of infants exposed to Prepidil gel in utero<i>.</i> Deceleration, intrauterine fetal sepsis, fetal depression and fetal acidosis have also been reported with administration of the endocervical gel. Still births, abnormal fetal heart rate and fetal distress have been reported with administration of Prostin E<sub>2</sub> vaginal gel and oral tablets [Canadian product].</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When used for termination of pregnancy, dinoprostone is not considered feticidal, but is used to terminate pregnancy due to its ability to stimulate uterine contractions; do not use if fetus has reached the stage of viability. A previable fetus may show transient life signs if aborted by dinoprostone. Failed pregnancy termination with dinoprostone should be completed by another method.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3946441\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Endogenous PGE<sub>2</sub> is present in breast milk (Shimizu 1992).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3946483\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, insert: Fetal heart rate, uterine activity, progression of cervical dilation and effacement</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Uterine activity; excessive uterine activity is contractions &gt; 5 per 10 minutes and/or the internal tonus consistently &gt; 15 mmHg.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Suppository: Confirmation of fetal death</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160932\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Dinoprostone (prostaglandin E<sub>2</sub>) is an endogenous hormone found in low concentrations in most tissues of the body. When administered as an abortifacient, it stimulates uterine contractions similar to those seen during natural labor. When administered for labor induction, it relaxes the smooth muscle of the cervix allowing dilation and passage of the fetus through the birth canal.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160947\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action (uterine contractions): Vaginal suppository: Within 10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Vaginal insert: 0.3 mg/hour over 12 hours; Vaginal suppository: Up to 2-3 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Vaginal suppository: Slow </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Metabolized in the lungs; forms metabolites which are further metabolized in the liver and kidney </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 2.5-5 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, plasma: Endocervical gel: 30-45 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine; feces (small amounts)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323113\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Prepidil Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/3 g (3 g): $679.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>INST</b> (Cervidil Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $449.96</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suppository</b> (Prostin E2 Vaginal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (5): $13,249.02</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F160951\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Cervidil (AU, MY, NZ);</li>\n      <li>Cerviprime (IN, VN);</li>\n      <li>Cerviprost (AT, RU);</li>\n      <li>Glandin E2 (LK);</li>\n      <li>Minprostin (NO, SE);</li>\n      <li>Minprostin E(2) (DE, DK);</li>\n      <li>Prandin E2 (ZA);</li>\n      <li>Prepidil (AE, AT, BE, BG, BH, CO, CY, CZ, EG, ES, FR, HN, HR, HU, IL, IQ, IR, IT, JO, KW, LU, LY, MY, NL, OM, PK, PL, QA, SA, SK, SY, YE, ZA);</li>\n      <li>Prepidyl (UA);</li>\n      <li>Primigyn (PH);</li>\n      <li>Primiprost (IN);</li>\n      <li>Prolisina E2 (AR);</li>\n      <li>Propess (AE, BR, CN, ES, FI, FR, HK, IL, LB, PH, SA, SE);</li>\n      <li>Propess Vag SR (KR);</li>\n      <li>Prostaglandina E2 (ES);</li>\n      <li>Prostarmon E (TW);</li>\n      <li>Prostenon (EE);</li>\n      <li>Prostin E2 (AE, AT, BE, BF, BG, BH, BJ, CH, CI, CY, EG, ET, GB, GH, GM, GN, GR, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IT, JO, KE, KW, LR, LU, LY, MA, ML, MR, MT, MU, MW, NE, NG, NL, OM, PT, QA, SA, SC, SD, SG, SL, SN, SY, TH, TN, TR, TW, TZ, UG, YE, ZA, ZM, ZW);</li>\n      <li>Prostin E2 Vaginal Cream (AU);</li>\n      <li>Prostin E2 Vaginal Gel (NZ);</li>\n      <li>Prostin VR (LU);</li>\n      <li>Prostine (FR);</li>\n      <li>Prostine E2 (VN);</li>\n      <li>Prostyn YE 2 (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ACOG Committee on Practice Bulletins - Obstetrics, &quot;ACOG Practice Bulletin No.107: Induction of Labor,&quot;<i>Obstet Gynecol</i>, 2009, 114(2 Pt 1):386-97.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dinoprostone-drug-information/abstract-text/19623003/pubmed\" target=\"_blank\" id=\"19623003\">19623003</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cervidil (dinoprostone vaginal insert) [package insert]. Parsippany, NJ: Ferring Pharmaceuticals; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cervidil (dinopostone vaginal insert) [package insert]. Toronto, Ontario: Ferring Inc.; September 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cusick W, Leuci D, Viscarello RR, et al, &ldquo;Anaphylactoid Syndrome of Pregnancy After Intracervical Dinoprostone for Cervical Ripening: A Report of 3 Cases,&rdquo; <i>J Reprod Med</i>, 2005, 50(3):225-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dinoprostone-drug-information/abstract-text/15841940/pubmed\" target=\"_blank\" id=\"15841940\">15841940</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Institute for Safe Medication Practices (ISMP), &ldquo;Dinoprostone dosage forms confused,&rdquo; ISMP Medication Safety Alert, August 22, 2013. Available at http://www.ismp.org/Newsletters/acutecare/issue.aspx?id=55</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novakov A, Segedi D, Milasinovic L, et al, &ldquo;Induction of Labor by Endocervical Application of Prostaglandins and Intravenous Infusion of Oxytocin in Post-term Pregnancy,&rdquo; <i>Med Pregl</i>, 1998, 51(9-10):419-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/dinoprostone-drug-information/abstract-text/9863332/pubmed\" target=\"_blank\" id=\"9863332\">9863332</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prepidil (dinosprostone) [prescribing information]. Montr&eacute;al, Qu&eacute;bec: Pharmacia and Upjohn; September 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prostin E2 (dinoprostone) [prescribing information]. Montr&eacute;al, Qu&eacute;bec: Pfizer Enterprises; September 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prostin E2 (dinoprostone) [prescribing information]. New York, NY: Pharmacia and Upjohn; April 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prostin E2 vaginal gel (dinoprostone) [prescribing information]. Montr&eacute;al, Qu&eacute;bec: Pfizer Enterprises; February 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9368 Version 114.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708703\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F160960\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F160961\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F161000\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F160964\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F3946482\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F160943\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F160929\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F15671160\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F160945\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132414\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F160944\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F161006\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F160936\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F160948\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F160933\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299208\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F160938\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3946439\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3946441\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3946483\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F160932\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F160947\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323113\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F160951\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9368|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=dinoprostone-patient-drug-information\" class=\"drug drug_patient\">Dinoprostone: Patient drug information</a></li></ul></div></div>","javascript":null}